KYNB
Kyntra BioยทNASDAQ
--
--(--)
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About KYNB
Kyntra Bio, Inc.
350 Bay Street, Suite 100 #6009, San Francisco, CA 94133
--
Kyntra Bio, Inc., was incorporated in Delaware in 1993. The company is a biopharmaceutical company focused on the development of new therapies in the frontiers of cancer biology and anemia. The company is developing FG-3246, a potential first-in-class antibody-drug conjugate targeting CD46 for the treatment of metastatic castration-resistant prostate cancer and potentially other cancers. The program also includes the development of FG-3180, a related CD46 targeted positron emission tomography biomarker and imaging agent.
Company Financials
EPS
KYNB has released its 2025 Q3 earnings. EPS was reported at -3.25, versus the expected -0.1, missing expectations. The chart below visualizes how KYNB has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
KYNB has released its 2025 Q3 earnings report, with revenue of 1.08M, reflecting a YoY change of 774.80%, and net profit of 200.64M, showing a YoY change of 1274.41%. The Sankey diagram below clearly presents KYNB's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
